These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29718026)

  • 1. Pushing the limits: developing a new standard of care for psoriasis.
    Weinberg JM
    Cutis; 2018 Mar; 101(3S):4. PubMed ID: 29718026
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination therapy of biologics with traditional agents in psoriasis.
    Guenther LC
    Skin Therapy Lett; 2011 Jun; 16(6):1-3. PubMed ID: 21833461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM; Saini R
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of biologics and other systemic agents in the treatment of pediatric psoriasis.
    Wright NA; Piggott CD; Eichenfield LF
    Semin Cutan Med Surg; 2010 Mar; 29(1):20-7. PubMed ID: 20430304
    [No Abstract]   [Full Text] [Related]  

  • 5. Consecutive use of different biological therapies in the treatment of psoriasis.
    Costanzo A; Papoutsaki M; Mazzotta A; Chimenti S
    Br J Dermatol; 2007 Aug; 157(2):394. PubMed ID: 17553044
    [No Abstract]   [Full Text] [Related]  

  • 6. A host of novel agents for treating psoriasis, psoriatic arthritis stir interest.
    Lamberg L
    JAMA; 2003 Jun; 289(21):2779-80, 2783. PubMed ID: 12783895
    [No Abstract]   [Full Text] [Related]  

  • 7. Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).
    Chiricozzi A; Saraceno R; Novelli L; Fida M; Caso F; Scarpa R; Costa L; Perricone R; Romanelli M; Chimenti S; Chimenti MS
    Expert Opin Ther Pat; 2016 Jul; 26(7):757-66. PubMed ID: 27266423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ustekinumab for the treatment of HIV psoriasis.
    Paparizos V; Rallis E; Kirsten L; Kyriakis K
    J Dermatolog Treat; 2012 Dec; 23(6):398-9. PubMed ID: 21787206
    [No Abstract]   [Full Text] [Related]  

  • 9. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab.
    Downs AM
    Br J Dermatol; 2010 Aug; 163(2):433-4. PubMed ID: 20456344
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors.
    Famenini S; Sako EY; Wu JJ
    Am J Clin Dermatol; 2014 Feb; 15(1):45-50. PubMed ID: 24281789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical experience of biologics for treatment of very severe psoriasis: a retrospective case cohort study of patients with a baseline Psoriasis Area and Severity Index greater than 20.
    Ponnambath N; Kalavala M; Anstey AV; Piguet V; Ingram JR
    Clin Exp Dermatol; 2016 Jan; 41(1):95-6. PubMed ID: 25817265
    [No Abstract]   [Full Text] [Related]  

  • 12. [Biological dermatologic agents. The Danish Society of Dermatology].
    Iversen L; Kragballe K;
    Ugeskr Laeger; 2007 Mar; 169(12):1100. PubMed ID: 17394811
    [No Abstract]   [Full Text] [Related]  

  • 13. [New therapies in psoriasis].
    Ferrándiz C
    Med Clin (Barc); 2007 Sep; 129(10):377-8. PubMed ID: 17915133
    [No Abstract]   [Full Text] [Related]  

  • 14. What's new in psoriasis? Analysis of the clinical significance of new guidelines and systematic reviews on psoriasis published in 2008 and 2009.
    Warren RB; Brown BC; Grindlay DJ; Griffiths CE
    Clin Exp Dermatol; 2010 Oct; 35(7):688-91; quiz 692. PubMed ID: 20545953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
    Wu JJ; Poon KY; Bebchuk JD
    J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of childhood psoriasis].
    Clabaut A; Viseux V;
    Ann Dermatol Venereol; 2010 May; 137(5):408-15; quiz 401, 417. PubMed ID: 20470927
    [No Abstract]   [Full Text] [Related]  

  • 17. Psoriasis: targeting therapy towards the inflammatory cascade.
    Miteva M
    Am J Clin Dermatol; 2010; 11 Suppl 1():11-3. PubMed ID: 20586499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on pediatric psoriasis, Part 2: Therapeutic management.
    Silverberg NB
    Cutis; 2010 Oct; 86(4):172-6. PubMed ID: 21140923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics.
    Levine D; Strober BE
    Semin Cutan Med Surg; 2010 Mar; 29(1):28-34. PubMed ID: 20430305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond Psoriasis: Novel Uses for Biologic Response Modifiers in Pediatric Dermatology.
    Bellodi-Schmidt F; Shah KN
    Pediatr Dermatol; 2016; 33(1):18-27. PubMed ID: 26607958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.